- Advertise
- Contact Editorial
- Editorial Submission Guidelines
- Contact MJH Life Sciences
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2023 MJH Life Sciences™ and Pharmaceutical Executive. All rights reserved.
Pharmaceutical Executive-08-01-2021
Why the Pandemic is Rewriting the Biopharma Rule Book
August 10, 2021
Back Page
41
8
Changes necessitated by COVID will drive unprecedented transformation of industry.
Primary Care in Crisis: PCP Navigation in a Specialty World
August 10, 2021
Features
41
8
COVID-19 may be the latest challenge to primary care physicians, but it’s just one of many threatening the profession, including the increased focus on specialty drug markets—if PCPs are left out of the equation.
A Brave New World: Optimizing Access in Wake of COVID
August 10, 2021
Features
41
8
The top changes necessary in planning and designing pharma market access plans, including a revamp of the payer-value equation at pivotal points in the product life cycle.
By Any Genes Necessary: The Role of MEAs for Gene Therapies
August 10, 2021
Features
41
8
Examining why the cost and administration of these treatments are well suited to managed entry agreements—and which approach to MEA may prove to be the most commercially viable for manufacturers.
A Framework for Future: Strengthening Market Access Competencies
August 10, 2021
Features
41
8
The BCG Market Access Roundtable presents an updated view of its access competencies framework first published five years ago.
Value Risk and Reward: Taking Stock of Value-Based Contracts in Pharma
August 10, 2021
Features
41
8
A look at how VBC agreements between drug manufacturers and payers—which reimburse for pre-specified treatment outcomes—have measured up so far in reducing healthcare costs, and the opportunities still untapped to drive true value for both sides and the patients they serve.
Capitalizing on Collaboration: The Effort to Sustain Pandemic-Partnering Momentum
August 10, 2021
Features
41
8
Biopharma leaders and experts gather to discuss the future of pharma collaboration and tackling critical public health needs—together.
A Global Vision for Access
August 10, 2021
Executive Profile
41
8
Ester Banque, senior vice president and head of Intercontinental Commercial at Bristol Myers Squibb, talks purpose and perseverance—both in her own career journey and her group’s mission to topple barriers to drug access in diverse and hard-to-reach regions.
Early Payer-Related Lessons for Pharma Post-Aduhelm Approval
August 10, 2021
Managed Markets
41
8
Initial coverage discussions put the focus on three key factors.
Biotech Capital Markets Continue to Underperform
August 10, 2021
Finance
41
8
But could there be a shift in momentum?
Managing the People Side of AI Adoption
August 10, 2021
Technology
41
8
Accelerated implementation of AI platforms among pharma sales teams has highlighted the importance of the human factor.
Pandemic Heightens Concern Over Workplace Burnout
August 10, 2021
Leadership
41
8
For leaders, shifting mindsets and altering dynamics can help.
Contention Swirls Around COVID Patent Waivers
August 10, 2021
Global Report
41
8
Report claims an imbalance in influence of tech-transfer decisions.
Drug Prices Targeted in Biden Executive Order
August 10, 2021
Washington Report
41
8
Sweeping competition initiative drills in on cost reduction.
COVID, Post-COVID, and Long-Haul COVID
August 10, 2021
From the Editor
41
8
Still plenty to learn about the virus even after year-plus long pandemic
The Art of Access, Connection
August 10, 2021
Chairman’s Letter
41
8
Collaboration shines through year of COVID.
Pharmaceutical Executive, August 2021 Issue (PDF)
August 09, 2021
Issue PDF
41
8
Click the title above for a link to open the Pharmaceutical Executive August 2021 issue in an interactive PDF format.